Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0837 • ACR Convergence 2024
Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome
Yuanxuan Xia¹, Jin Liu¹, Alexander Pearlman¹, Brian Mog¹, Elana Shaw¹, Kyle J. Kaeo¹, Colin Gliech¹, Brock Moritz¹, Tolulope Awosika¹, Sarah DiNapoli¹, Stephanie Glavaris¹, Jiaxin Ge¹, Tushar Nichakawade¹, Nikita Marcou¹, Suman Paul¹, Drew Pardoll¹, Chetan Bettegowda¹, Daniel Goldman², Michelle Petri², Antony Rosen¹, Kenneth W. Kinzler¹, Shibin Zhou¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Available drugs to treat autoimmune diseases are indiscriminate, suppressing self-reactive and protective immune responses alike. This lack of therapeutic precision results in infection and…
Abstract Number: 0101 • ACR Convergence 2024
Metabolomic Profiling Reveals a Role for Citric Acid Cycle Dysfunction in Antiphospholipid Syndrome Neutrophils
Ajay Tambralli¹, Megan Radyk¹, Kaitlyn Sabb¹, Li Zhang¹, Harrison Wong¹, Emily Becker¹, Srilakshmi Yalavarthi¹, Claire Hoy¹, Cyrus Sarosh², Jacqueline Madison¹, Yu Zuo¹, Jason Knight¹ and Costas Lyssiotis¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI
Background/Purpose: As early effectors of the immune response, neutrophils must access energy rapidly. Neutrophils rely on glycolysis for antimicrobial functions such as phagocytosis and reactive…
Abstract Number: 0117 • ACR Convergence 2024
Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population
Daniel Bar¹, Stanley Niznik², Shiri Spielman³, Rotem Semo-Oz⁴, Assaf Barg³, Sarina Levy-Mendelovich³, Gili Kenet², Nancy Agmon- Levin² and Irit Tirosh⁵, ¹Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, HaMerkaz, Israel, ²Sheba Medical Center, Tel Aviv, Israel, ³Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Tel Aviv, Israel, ⁴Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, Israel, ⁵Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Savyon, Israel
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous or microvascular thrombosis, obstetric morbidity and/or non-thrombotic manifestations. The 2023 ACR/EULAR APS…
Abstract Number: 0838 • ACR Convergence 2024
The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS
Kavya Sugur¹, Emily Chong¹, Srilakshmi Yalavarthi², Katarina Kmetova³, Lyndsay Kluge¹, Wenying Liang², Cyrus Sarosh⁴, NaveenKumar Somanathapura K², Jacqueline Madison², Ajay Tambralli², Jason Knight² and Yu Zuo², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…
Abstract Number: 0102 • ACR Convergence 2024
Single-cell Profiling of Dermal Endothelial Cells Identifies Unique Molecular Pathways Associated with Small-Vessel Events and Nephropathy in Antiphospholipid Syndrome
Wenying Liang¹, Qinmengge Li¹, Jacqueline Madison¹, Rachael Wasikowski², Srilakshmi Yalavarthi¹, Cyrus Sarosh³, Yu Zuo¹, Pei-Suen Tsou¹, Lam Tsoi¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan, Dept. of Dermatology, Ann Arbor, MI, ³University of Michigan, Temperance, MI
Background/Purpose: Beyond thrombotic events, antiphospholipid syndrome (APS) is also associated with an organ-threatening small-vessel vasculopathy that lacks specific treatments. A soon-to-be-published skin biopsy study focusing…
Abstract Number: 0118 • ACR Convergence 2024
Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Erik Cimé-Aké¹, Gabriela Hernández-Molina², Amaya Llorente-Chávez³ and Eduardo Martin Nares², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Hematology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: The 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) were recently published. The new criteria require an entry criterion and employe a…
Abstract Number: 0839 • ACR Convergence 2024
Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity
Haoyu Pan, Xiaohan Wei, Jinyi Qian, Shuyi Yu, Zhixia Yang, Zetao Ding, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized with the presence of pathogenic antiphospholipid antibodies (aPL) by autoreactive B cells. However, it remains…
Abstract Number: 0103 • ACR Convergence 2024
CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome
chun Li, Peking University People's Hospital, Beijing, China
Background/Purpose: To investigate the relationship between CD10highLow-Density Granulocytes (LDG) and disease activity in antiphospholipid syndrome(APS).Methods: This study included 99 patients with APS who were treated…
Abstract Number: 0119 • ACR Convergence 2024
Clinical and Serological Distinctions and Evolutionary Predictors in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Multicenter Cohort Analysis
Basant Elnady¹, Ziyad Alakkas², Sultana Abdulaziz³, Hussain Halabi⁴, Ahmed A. G. Ibrahim⁵, Hoda E. Draz⁵, Mohammed Attar⁶, Hassan Daghasi⁷, Abeer Alhalwani⁸, Reman Shaker⁹ and Ghadeer Maher Elsheikh¹⁰, ¹Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, ²King Faisal Medical Complex, Taif, Saudi Arabia, ³King Fahad Hospital, Jeddah, Saudi Arabia, ⁴King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, ⁵Benha University, Benha, Egypt, ⁶al hada armed forces hospital, Taif, Saudi Arabia, ⁷Alhada military hospital, Taif, Saudi Arabia, ⁸East Jeddah hospital, Jeddah, Saudi Arabia, ⁹King Faisal Specialist Hospital and Research centre, Jeddah, Saudi Arabia, ¹⁰Menoufia University, Menoufia, Egypt
Background/Purpose: Antiphospholipid syndrome (APS) is closely linked with Systemic Lupus erythematosus (SLE) and can influence patient outcomes. The interplay between APS and SLE, including the evolution…
Abstract Number: 0840 • ACR Convergence 2024
The Platelet Adenosinergic Axis as a Novel Therapeutic Target for Thrombotic APS
NaveenKumar Somanathapura K¹, Thalia Newman², Srilakshmi Yalavarthi¹, Bruna Mazetto Fonseca¹, Kaitlyn Sabb¹, Katarina Kmetova³, Emily Chong¹, Caroline Ranger¹, Cyrus Sarosh⁴, Jacqueline Madison¹, Ajay Tambralli¹, Jordan Schaefer¹, Michael Holinstat¹, Yu Zuo¹ and Jason Knight¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: How to most effectively inhibit antiphospholipid antibodies (aPL)-mediated platelet activation remains incompletely understood. CD73 is an ectoenzyme expressed on the platelet surface that generates…
Abstract Number: 0104 • ACR Convergence 2024
Proteomic Analysis Identifies Neutrophil Defensin 1 as a Biological Marker for Antiphospholipid Syndrome
Yuebing Wang¹ and chun Li², ¹Department of Rheumatology and Immunology, Peking University People’s Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Beijing, China, Beijing, China, ²Peking University People's Hospital, Beijing, China
Background/Purpose: Antiphospholipid syndrome (APS) is a distinct type of thrombophilia caused by autoantibodies, characterized by repeated thrombosis and complications during pregnancy. This study aimed to…
Abstract Number: 0120 • ACR Convergence 2024
Vascular Liver Disorders in Patients with Antiphospholipid Syndrome: A Retrospective National Multicentre Study
Mathilde Katims¹, Marc Pineton de Chambrun², Cecine Yelnik³, Arthur Mageau⁴, Ada Clarke¹, Matthias Papo⁵, Zahir Amoura⁶, Marc Lambert³, Thomas Papo⁴, Laure Delaval⁷, Pierre-Emmanuel Rautou⁸, Nathalie Costedoat-chalumeau⁹ and Karim Sacré⁴, ¹Assistance Publique Hopitaux de Paris, Paris, France, ²Sorbonne Université, Paris, France, ³Université de Lille, Lille, France, ⁴Université Paris Cité, Paris, France, ⁵Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris, Paris, France, ⁶French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France, ⁷Hopital Delafontaine, Saint Denis, France, ⁸Université Paris Cité, Clichy, France, ⁹University Paris Cité, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by autoantibodies that recognize cell surface phospholipids and phospholipid binding proteins. The result is an increased…
Abstract Number: 0841 • ACR Convergence 2024
Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Michael Parides¹, Danieli Andrade², Diana Paredes-Ruiz³, Maria Tektonidou⁴, Vittorio Pengo⁵, Savino Sciascia⁶, Cecilia Nalli⁷, Guilherme Ramires de Jesús⁸, Paul Fortin⁹, Maria Efthymiou¹⁰, H Michael Belmont¹¹, Michelle Petri¹², Ricard Cervera¹³, Leslie Skeith¹⁴, TATSUYA ATSUMI¹⁵, Chary Lopez-Pedrera¹⁶, Yu Zuo¹⁷, David Branch¹⁸, Rohan Willis¹⁹, Nina Kello²⁰, Zhuoli Zhang²¹, Esther Rodriguez-Almaraz²², Bahar Artim Esen²³, Jose Pardos-Gea²⁴, Guillermo Pons-Estel²⁵, Giulia Pazzola²⁶, Hui Shi¹⁷, Ali Duarte-Garcia²⁷, Medha Barbhaiya¹, Cécile Yelnik²⁸, Pierluigi Meroni²⁹, Robert Roubey³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Jacob Rand³³ and Doruk Erkan¹, and on behalf of APS ACTION, ¹Hospital for Special Surgery, New York, NY, ²University of São Paulo, São Paulo, SP, Brazil, ³Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ⁶University of Turin, Torino, Turin, Italy, ⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁸Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ⁹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁰University College London, London, United Kingdom, ¹¹NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴University of Calgary, Calgary, ON, Canada, ¹⁵Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁹University of Texas Medical Branch, Galveston, TX, ²⁰Northwell Health, Brooklyn, NY, ²¹Peking University First Hospital, Beijing, China, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁴Vall d'Hebron University Hospital, Barcelona, Spain, ²⁵CREAR, Rosario, Argentina, ²⁶Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²⁷Mayo Clinic, Rochester, MN, ²⁸lille university, Lille, France, ²⁹IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ³⁰Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³Weill Cornell Medical Center, Bronx, NY
Background/Purpose: There is a lack of high-quality data to inform risk-stratified long-term thrombosis prevention strategies in patients with persistently positive antiphospholipid antibodies (aPL). The APS…
Abstract Number: 0105 • ACR Convergence 2024
Novel Autoantibodies Identified in the Antiphospholipid Syndrome
Shikai Hu¹, Yangzhong Zhou¹, Menghua Cai¹, Mengtao Li² and JIULIANG ZHAO¹, ¹Peking Union Medical College Hospital, Beijing, China, ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China
Background/Purpose: The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous, or microvascular thrombosis, recurrent pregnancy morbidity, or non-thrombotic manifestations in the…
Abstract Number: 0121 • ACR Convergence 2024
Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers
Liala Moschetti¹, Savino Sciascia², Micaela Fredi³, Mattia Zappa⁴, Massimo Radin⁵, Ilaria Cavazzana³, Stefania Affatato⁶, Cecilia Nalli⁷, Laura Andreoli⁸, Federico Alberici⁹, Franco Franceschini¹, Dario Roccatello¹⁰ and Angela Tincani¹¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²University of Turin, Torino, Turin, Italy, ³Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, ERN ReCONNET; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, ⁴Nephrology Unit and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, ⁵University of Turin, Turin, Italy, ⁶Nephrology Unit, University of Brescia, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁸University of Brescia, Brescia, Italy, ⁹Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, ¹⁰Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID) and Department of Clinical and Biological Sciences; San Giovanni Bosco Hospital and University of Turin, Italy, Turin, Italy, ¹¹ASST Spedali Civili-University of Brescia, Brescia, Italy
Background/Purpose: Antiphospholipid antibodies nephropathy (aPL-N) is defined by thrombotic microangiopathy (TMA) early lesions and late lesions such fibro-intimal hyperplasia with luminal obliteration/organized thrombi, fibrous arterial/arteriolar…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].